Noliterax 10+2,5 mg filmovertrukne tabletter Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

noliterax 10+2,5 mg filmovertrukne tabletter

les laboratoires servier - indapamid (vandfri), perindoprilarginin - filmovertrukne tabletter - 10+2,5 mg

Paraterax 8+2,5 mg tabletter Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

paraterax 8+2,5 mg tabletter

les laboratoires servier - indapamid (vandfri), perindopril tert-butylamin - tabletter - 8+2,5 mg

Viacoram 3,5+2,5 mg tabletter Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

viacoram 3,5+2,5 mg tabletter

les laboratoires servier - amlodipin, perindoprilarginin - tabletter - 3,5+2,5 mg

Valdoxan Европейский союз - датский - EMA (European Medicines Agency)

valdoxan

les laboratoires servier - agomelatin - depressiv lidelse, major

Thymanax Европейский союз - датский - EMA (European Medicines Agency)

thymanax

les laboratoires servier - agomelatin - depressiv lidelse, major

Libroxar 2+0,5 mg resoribletter, sublinguale Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

libroxar 2+0,5 mg resoribletter, sublinguale

laboratoires smb s.a. - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg

Libroxar 8+2 mg resoribletter, sublinguale Дания - датский - Lægemiddelstyrelsen (Danish Medicines Agency)

libroxar 8+2 mg resoribletter, sublinguale

laboratoires smb s.a. - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 8+2 mg

Tibsovo Европейский союз - датский - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.